Matinas up on safety panel nod for fungal infection trial progression

Matinas BioPharma Holdings

16/12/2021 13:39

** Shares of Matinas BioPharma Holdings Inc  MTNB.A  rise 2%
to $1.02 premarket
    ** Co says independent Data and Safety Monitoring Board has
unanimously recommended progression to fourth cohort of patients
in an ongoing mid-stage trial testing its experimental therapy,
MAT2203, for the treatment of cryptococcal meningitis
    ** Cryptococcal meningitis is a fungal infection and
inflammation of the membranes covering the spinal cord and brain
    ** Enrollment in the next randomized cohort, with 40
active-treatment patients, is expected to begin in early Q3 2022
    ** The study is financially supported by the National
Institutes of Health
    ** Stock down about ~26.5% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))